131 related articles for article (PubMed ID: 38507062)
1. Pharmacokinetics, mass balance, and metabolism of [
Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38507062
[TBL] [Abstract][Full Text] [Related]
2. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study.
Bian Y; Ma S; Yao Q; Hu T; Ge M; Li H; Zheng S; Gu Z; Feng H; Yu Z; Huang C; Zhang H; Zhao L; Miao L
Expert Opin Investig Drugs; 2024 Jan; 33(1):63-72. PubMed ID: 38224050
[TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism, excretion, and safety of [
Zhou C; Xie L; Liu W; Zhang L; Zhou S; Wang L; Chen J; Li H; Zhao Y; Zhu B; Ding S; Zhang C; Shao F
Ann Transl Med; 2021 May; 9(10):867. PubMed ID: 34164501
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
7. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [
Zhou S; Shao F; Xu Z; Wang L; Jin K; Xie L; Chen J; Liu Y; Zhang H; Ou N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):563-573. PubMed ID: 28730290
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
9. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
10. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [
Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H
Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
Ma Y; Zhao H; Xue J; Liu L; Yang N; Zhang Y; Yang H; Hong S; Xiong Y; Zhang Z; Zeng L; Pan H; Zhou C; Zhang Y; Wang X; Han X; Wan X; Shao Y; Liu J; Yang Y; Huang Y; Zhao Y; Fang W; Li S; Zhang L
Eur J Cancer; 2022 Sep; 173():238-249. PubMed ID: 35940055
[TBL] [Abstract][Full Text] [Related]
12. Excretion balance and pharmacokinetics following a single oral dose of [
Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
[TBL] [Abstract][Full Text] [Related]
14. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Yang Y; Min J; Yang N; Yu Q; Cheng Y; Zhao Y; Li M; Chen H; Ren S; Zhou J; Zhuang W; Qin X; Cao L; Yu Y; Zhang J; He J; Feng J; Yu H; Zhang L; Fang W
Signal Transduct Target Ther; 2023 Aug; 8(1):301. PubMed ID: 37574511
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
16. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
17. Metabolic disposition of [
Wang L; Guo L; Wang Y; Guo R; Xu Z; Gao Z; Xie L; Chen J; Chen Y; Liu Y; Zhang H; Bao L; Xu W; Zhu M; Shao F; Shu Y
Br J Clin Pharmacol; 2021 Mar; 87(3):1475-1485. PubMed ID: 32959915
[TBL] [Abstract][Full Text] [Related]
18. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
19. Mass balance study of [
Ge X; Ma S; Yan S; Wu Y; Chen C; Tang C; Zhan Y; Bian YC; Shen K; Feng S; Gao X; Zhong D; Zhang H; Miao LY; Diao XX
Xenobiotica; 2023 Feb; 53(2):69-83. PubMed ID: 36745485
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism and excretion of [
Vuu I; Dahal UP; Wang Z; Shen X; Rodgers J; Wahlstrom J; Houk B
Cancer Chemother Pharmacol; 2022 Oct; 90(4):357-367. PubMed ID: 36063185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
